Irish drugmaker Actavis said that its adjusted earnings for the fourth quarter will be a bit better than it previously expected.
Actavis said in October that it expected to earn between $2.95 and $3.05 per share in the fourth quarter, excluding one-time charges and gains. It now says its net income will be above the high end of that estimate.
According to FactSet, analysts were forecasting earnings of $2.96 per share on average.
Actavis PLC is scheduled to report its fourth-quarter results on Feb. 20.
Date: January 14, 2014
Source: Associated Press
Filed Under: Drug Discovery